| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1696 | 2016 |
| Targeting CD38 with daratumumab monotherapy in multiple myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1362 | 2015 |
| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ... Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016 | 1016 | 2016 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 991 | 2019 |
| Continuous lenalidomide treatment for newly diagnosed multiple myeloma A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ... New England Journal of Medicine 366 (19), 1759-1769, 2012 | 948 | 2012 |
| First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 … B Eichhorst, AM Fink, J Bahlo, R Busch, G Kovacs, C Maurer, E Lange, ... The lancet oncology 17 (7), 928-942, 2016 | 780* | 2016 |
| Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ... Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016 | 521 | 2016 |
| A physical mechanism for coupling bone resorption and formation in adult human bone TL Andersen, TE Sondergaard, KE Skorzynska, F Dagnaes-Hansen, ... The American journal of pathology 174 (1), 239-247, 2009 | 453 | 2009 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 392 | 2019 |
| Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells T Standal, C Seidel, Ø Hjertner, T Plesner, RD Sanderson, A Waage, ... Blood, The Journal of the American Society of Hematology 100 (8), 3002-3007, 2002 | 335 | 2002 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... The Lancet Oncology 22 (11), 1582-1596, 2021 | 308 | 2021 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 265 | 2019 |
| Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia CH Geisler, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B Lund, ... | 264 | 1991 |
| Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma NWCJ van de Donk, P Moreau, T Plesner, A Palumbo, F Gay, JP Laubach, ... Blood, The Journal of the American Society of Hematology 127 (6), 681-695, 2016 | 246 | 2016 |
| Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR T Plesner, N Behrendt, M Ploug Stem cells 15 (6), 398-408, 1997 | 246 | 1997 |
| A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. R Popat, T Plesner, F Davies, G Cook, M Cook, P Elliott, E Jacobson, ... British journal of haematology 160 (5), 2013 | 240 | 2013 |
| Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation P Boissy, TL Andersen, BM Abdallah, M Kassem, T Plesner, JM Delaissé Cancer research 65 (21), 9943-9952, 2005 | 238 | 2005 |
| Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma T Casneuf, XS Xu, HC Adams III, AE Axel, C Chiu, I Khan, T Ahmadi, ... Blood advances 1 (23), 2105-2114, 2017 | 226 | 2017 |
| Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura P Brændstrup, OW Bjerrum, OJ Nielsen, BA Jensen, NT Clausen, ... American journal of hematology 78 (4), 275-280, 2005 | 211 | 2005 |
| Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia S Gudbrandsdottir, HS Birgens, H Frederiksen, BA Jensen, MK Jensen, ... Blood, The Journal of the American Society of Hematology 121 (11), 1976-1981, 2013 | 203 | 2013 |